C07K 2317/30
Characterized by aspects of specificity or valency
Official title: characterized by aspects of specificity or valency
C07K2317/30 (Characterized by aspects of specificity or valency) appears on 12,532 US grants and 23,384 published applications in this corpus.
Search patents in C07K- Granted patents
- 12,532
- Published applications
- 23,384
- Assignees
- 4,751
- Inventors
- 30,196
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 3 | 0 |
| 1990 | 4 | 0 |
| 1991 | 6 | 0 |
| 1992 | 6 | 0 |
| 1993 | 15 | 0 |
| 1994 | 18 | 0 |
| 1995 | 20 | 0 |
| 1996 | 22 | 0 |
| 1997 | 60 | 0 |
| 1998 | 68 | 0 |
| 1999 | 76 | 0 |
| 2000 | 73 | 0 |
| 2001 | 54 | 18 |
| 2002 | 49 | 112 |
| 2003 | 48 | 181 |
| 2004 | 62 | 190 |
| 2005 | 53 | 225 |
| 2006 | 79 | 222 |
| 2007 | 95 | 244 |
| 2008 | 104 | 257 |
| 2009 | 157 | 424 |
| 2010 | 181 | 433 |
| 2011 | 245 | 533 |
| 2012 | 286 | 617 |
| 2013 | 353 | 741 |
| 2014 | 426 | 914 |
| 2015 | 595 | 969 |
| 2016 | 645 | 1198 |
| 2017 | 786 | 1303 |
| 2018 | 806 | 1284 |
| 2019 | 839 | 1424 |
| 2020 | 929 | 1535 |
| 2021 | 930 | 1726 |
| 2022 | 913 | 1804 |
| 2023 | 811 | 1805 |
| 2024 | 1008 | 2098 |
| 2025 | 1019 | 1777 |
| 2026 | 686 | 1350 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Anti-galectin 3 antibodies and their use in epilepsy and related diseases6 Oct 2026US 12,752,015 B2Sunmed Therapeutic Limited
- Aggrecan binding immunoglobulins6 Oct 2026US 12,753,224 B2Ablynx N. V.
- Anti-MS4A4A antibodies and methods of use thereof6 Oct 2026US 12,753,225 B2Alector LLC
- TGFbeta1-binding immunoglobulins and use thereof6 Oct 2026US 12,753,226 B2Scholar Rock, Inc.
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof8 Oct 2026US 2026/0306651 A1MediLink Therapeutics (Suzhou) Co., Ltd.
- Radiolabeled met binding proteins for immuno-pet imaging8 Oct 2026US 2026/0306682 A1Regeneron Pharmaceuticals, Inc.
- Multi-receptor natural killer cells8 Oct 2026US 2026/0308225 A1Board of Regents, The University of Texas System
- Compostions of multispecific antigen binding polypeptides and methods of use8 Oct 2026US 2026/0308242 A1Revopsis Therapeutics, Inc.
Most cited
By later US patents
- Immunoglobulin variants1,380US 5,821,337 AGenentech, Inc. · 1998
- Production of chimeric antibodies - a combinatorial approach1,367US 5,565,332 ACambridge Antibody Technology Limited · 1996
- Humanized antibodies and methods for making them1,003US 6,054,297 AGenentech, Inc. · 2000
- Method for making humanized antibodies943US 6,407,213 B1Genentech, Inc. · 2002
- Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics940US 8,008,449 B2Medarex, Inc. · 2011